Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street

This article was originally published in RPM Report

Executive Summary

There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?

You may also be interested in...

FDA Risk Communication Strategy May Include Overhaul Of Labeling Language

As FDA assesses its new risk management powers and overall drug safety strategy, it continues to focus on how to revise what has been its primary communications tool for decades - product labeling

Next Chapter In The Amylin Chronicles: Job Cuts, Restructuring

Troubled by slower Byetta growth and uncertainty around the development of a long-acting version, Amylin will cut 25 percent of its San Diego workforce.

Amylin Speculation Intensifies: Byetta LAR May Be Delayed

Comparability studies could mean filing is impossible for first half of 2009, Amylin says.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts